Tea could improve memory, study showsOctober 25, 2004Drinking regular cuppas could help improve your memory, new research suggests. Results of laboratory tests by a team from the University of Newcastle upon Tyne found that green and black tea inhibit the activity of certain enzymes in the brain which are associated with memory. The findings, which are published in the academic journal, Phytotherapy Research, may lead to the development of a new treatment for a form of dementia which affects an estimated ten million people worldwide, Alzheimer's Disease. For their experiment, the research team, from Newcastle University's Medicinal Plant Research Centre, investigated the properties of coffee and green and black tea in a series of scientific experiments. Black tea - traditional English breakfast tea - is derived from the same plant as green tea, Camellia sinensis, but has a different taste and appearance because it is fermented. They found that both green and black tea inhibited the activity of enzymes associated with the development of Alzheimer's Disease, but coffee had no significant effect. Both teas inhibited the activity of the enzyme acetylcholinesterase (AChE), which breaks down the chemical messenger or neurotransmitter, acetylcholine. Alzheimer's is characterised by a drop in acetylcholine. Green tea and black tea also hinder the activity of the enzyme butyrylcholinesterase (BuChE), which has been discovered in protein deposits which are found on the brain of patients with Alzheimer's. Green tea went one step further in that it obstructed the activity of beta-secretase, which plays a role in the production of protein deposits in the brain which are associated with Alzheimer's disease. Scientists also found that it continued to have its inhibitive effect for a week, whereas black tea's enzyme-inhibiting properties lasted for only one day. There is no cure for Alzheimer's but it is possible to slow the development of the disease. Drugs currently on the market hinder the activity of AChE, and others are being developed which scientists hope will inhibit the activity of BuChE and beta-secretase. However, many of the drugs currently available, such as donepezil, have unpleasant side effects and the medical profession is keen to find alternatives. The Newcastle University researchers are now seeking funding to carry out further tests on green tea, which they hope will include clinical trials. Their aim is to work towards the development of a medicinal tea which is specifically aimed at Alzheimer's sufferers. The next step is to find out exactly which components of green tea inhibit the activity of the enzymes AChE, BuChE and beta-secretase. Lead researcher, Dr Ed Okello, who is also a lecturer with Newcastle University's School of Biology, said: "Although there is no cure for Alzheimer's, tea could potentially be another weapon in the armoury which is used to treat this disease and slow down its development. It would be wonderful if our work could help improve the quality of life for millions of sufferers and their carers. "Our findings are particularly exciting as tea is already a very popular drink, it is inexpensive, and there do not seem to be any adverse side effects when it is consumed. Still, we expect it will be several years until we are able to produce anything marketable. Dr Okello, himself a green tea drinker, said the findings of the research suggested tea could boost the memory of everyday drinkers: "The ageing politician, Tony Benn, is a prime example of somebody who drinks tea and has a fantastic memory. He is said to drink 18 pints a day and has a very sharp mind for a man of his age," he added. Prof Clive Ballard, director of research, Alzheimer's Society, said: "This interesting research builds on previous evidence that suggests that green tea may be beneficial due to anti-oxidant properties. Certainly the effect on the cholinesterase enzyme (the target of current anti-dementia drugs such as Aricept) and beta-secretase (an enzyme which is important in the build up of plaques) is very exciting and requires further investigation." Newcastle upon Tyne, University of |
|||||||||||||||||||||
| Related Alzheimer Disease Current Events and Alzheimer Disease News Articles Delirium in hospitalized adults: Situation critical, no relief available Every year as many as seven million adults in the United States experience delirium during hospitalization. New data demonstrate potential for early detection of Alzheimer's disease Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease. Another McGill/JGH breakthrough opens door to early Alzheimer's diagnosis A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital (JGH). Measuring brain atrophy in patients with mild cognitive impairment Scientists at the University of California, San Diego School of Medicine have shown that a fully automated procedure called Volumetric MRI - which measures the "memory centers" of the brain and compares them to expected size - is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease. Commonly used medications may produce cognitive impairment in older adults Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults. Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug. New test for mysterious metabolic diseases developed at Stanford/Packard Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism. Recalibrating 'fight or flight' A Canadian/U.S. research team has reported a novel approach to stimulating recovery from chronic stress disorders. Details of the therapeutic model, which exploits the natural dynamics of the body's "fight or flight" system, are published January 23 in the open-access journal PLoS Computational Biology Vitamin B does not slow cognitive decline in Alzheimer's A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease. Protecting patient privacy the new fashioned way Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act. More Alzheimer Disease Current Events and Alzheimer Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||